These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1973905)

  • 1. Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients.
    Rausch JL; Stahl SM; Hauger RL
    Biol Psychiatry; 1990 Jul; 28(1):73-8. PubMed ID: 1973905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gepirone in the treatment of major depression.
    Jenkins SW; Robinson DS; Fabre LF; Andary JJ; Messina ME; Reich LA
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):77S-85S. PubMed ID: 1973942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gepirone as a 5-HT1A agonist in the treatment of major depression.
    Rausch JL; Ruegg R; Moeller FG
    Psychopharmacol Bull; 1990; 26(2):169-71. PubMed ID: 1978370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of gepirone on neuroendocrine function and temperature in humans.
    Anderson IM; Cowen PJ; Grahame-Smith DG
    Psychopharmacology (Berl); 1990; 100(4):498-503. PubMed ID: 2157231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression.
    Amsterdam JD
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 May; 16(3):271-80. PubMed ID: 1350353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement.
    McGrath PJ; Stewart JW; Quitkin FM; Wager S; Jenkins SW; Archibald DG; Stringfellow JC; Robinson DS
    J Clin Psychopharmacol; 1994 Oct; 14(5):347-52. PubMed ID: 7806692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonergic anxiolytics and treatment of depression.
    Robinson DS; Alms DR; Shrotriya RC; Messina M; Wickramaratne P
    Psychopathology; 1989; 22 Suppl 1():27-36. PubMed ID: 2657837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
    Feiger AD; Heiser JF; Shrivastava RK; Weiss KJ; Smith WT; Sitsen JM; Gibertini M
    J Clin Psychiatry; 2003 Mar; 64(3):243-9. PubMed ID: 12716264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial.
    Rickels K; Schweizer E; DeMartinis N; Mandos L; Mercer C
    J Clin Psychopharmacol; 1997 Aug; 17(4):272-7. PubMed ID: 9241006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects.
    Meltzer HY; Maes M
    Biol Psychiatry; 1994 Mar; 35(5):316-23. PubMed ID: 8011800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique modulation of central 5-HT2 receptor binding sites and 5-HT2 receptor-mediated behavior by continuous gepirone treatment.
    Yocca FD; Eison AS; Hyslop DK; Ryan E; Taylor DP; Gianutsos G
    Life Sci; 1991; 49(24):1777-85. PubMed ID: 1682780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone.
    Robinson DS; Sitsen JM; Gibertini M
    Clin Ther; 2003 Jun; 25(6):1618-33. PubMed ID: 12860488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antiglucocorticoid treatment on 5-HT1A function in depressed patients and healthy subjects.
    Price LH; Cappiello A; Malison RT; McDougle CJ; Pelton GH; Schöllnhammer G; Heninger GR
    Neuropsychopharmacology; 1997 Oct; 17(4):246-57. PubMed ID: 9326749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.
    Amsterdam JD; Brunswick DJ; Gibertini M
    J Psychiatr Res; 2004; 38(3):259-65. PubMed ID: 15003431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls.
    Lesch KP; Mayer S; Disselkamp-Tietze J; Hoh A; Wiesmann M; Osterheider M; Schulte HM
    Biol Psychiatry; 1990 Oct; 28(7):620-8. PubMed ID: 1977479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in cortical 5HT2 receptor sensitivity after continuous gepirone treatment.
    Eison AS; Yocca FD
    Eur J Pharmacol; 1985 May; 111(3):389-92. PubMed ID: 2862051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain.
    Blier P; de Montigny C
    Synapse; 1987; 1(5):470-80. PubMed ID: 2905533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women.
    Fabre LF; Brown CS; Smith LC; Derogatis LR
    J Sex Med; 2011 May; 8(5):1411-9. PubMed ID: 21324094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties.
    Kaur Gill A; Bansal Y; Bhandari R; Kaur S; Kaur J; Singh R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Jul; 55(7):423-437. PubMed ID: 31347611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.